Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson
Jan 28, 2014
by Dave Williamson
How Gilead Sciences, Inc. Could Push Back on Sovaldi Pricing
The price for Gilead's new hepatitis C cure seems exorbitant to some, and now pharmacy benefit managers are starting to push back along with the protestors. Here's why Gilead's pricing will still probably hold.
HOW THE MOTLEY FOOL CAN HELP YOU
-
Premium Investing Guidance
Market beating stocks from our award-winning service
-
The Daily Upside Newsletter
Investment news and high-quality insights delivered straight to your inbox
-
Get Started Investing
You can do it. Successful investing in just a few steps
-
Win at Retirement
Secrets and strategies for the post-work life you want.
-
Find a Broker
Find the right brokerage account for you.
-
Listen to our Podcasts
Hear our experts take on stocks, the market, and how to invest.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.